CDX Simplify High Yield PLUS Credit Hedge ETF

IRVINE, Calif., March 1 /PRNewswire-FirstCall/ -- ChromaDex Corporation (BULLETIN BOARD: CDXC) , a world leader in phytochemical reference standards and contract testing services, announced the receipt of a U.S. General Services Administration (GSA) Supply Contract for scientific services. Effective March 1, 2010, the contract (GS-07F-0243W for Schedule 66 Scientific Equipment and Services) will streamline the process by which federal agencies can engage ChromaDex and purchase services, including all aspects of dietary supplement testing, analytical method development and validation, contract research services, report and manuscript preparation and laboratory technique training. "This long term supply contract enables government agencies to quickly and easily utilize ChromaDex services without going through lengthy competitive bid processes," said Frank Jaksch, CEO and co-founder of ChromaDex. "We currently serve a number of government agencies, and this contract will make it quicker and easier for them to do business with ChromaDex." About ChromaDex ChromaDex is a world leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable, "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools, products, and services to meet the regulatory, quality, efficacy and safety standards for their products. To learn more, visit http://www.chromadex.com/. Forward-Looking Statements Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law. DATASOURCE: ChromaDex Corporation CONTACT: Megan Lavine of Porter Novelli Life Sciences, +1-619-849-5388,mlavine@pnlifesciences.com Web Site: http://www.chromadex.com/

Copyright